These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 35979371)

  • 1. Genomic alteration of MTAP/CDKN2A predicts sarcomatoid differentiation and poor prognosis and modulates response to immune checkpoint blockade in renal cell carcinoma.
    Xu W; Anwaier A; Liu W; Wei G; Su J; Tian X; Xia J; Qu Y; Zhao J; Zhang H; Ye D
    Front Immunol; 2022; 13():953721. PubMed ID: 35979371
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pan-cancer analysis of CDKN2A alterations identifies a subset of gastric cancer with a cold tumor immune microenvironment.
    Deng C; Li ZX; Xie CJ; Zhang QL; Hu BS; Wang MD; Mei J; Yang C; Zhong Z; Wang KW
    Hum Genomics; 2024 May; 18(1):55. PubMed ID: 38822443
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma.
    Bakouny Z; Braun DA; Shukla SA; Pan W; Gao X; Hou Y; Flaifel A; Tang S; Bosma-Moody A; He MX; Vokes N; Nyman J; Xie W; Nassar AH; Abou Alaiwi S; Flippot R; Bouchard G; Steinharter JA; Nuzzo PV; Ficial M; Sant'Angelo M; Forman J; Berchuck JE; Dudani S; Bi K; Park J; Camp S; Sticco-Ivins M; Hirsch L; Baca SC; Wind-Rotolo M; Ross-Macdonald P; Sun M; Lee GM; Chang SL; Wei XX; McGregor BA; Harshman LC; Genovese G; Ellis L; Pomerantz M; Hirsch MS; Freedman ML; Atkins MB; Wu CJ; Ho TH; Linehan WM; McDermott DF; Heng DYC; Viswanathan SR; Signoretti S; Van Allen EM; Choueiri TK
    Nat Commun; 2021 Feb; 12(1):808. PubMed ID: 33547292
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genomic landscape of non-small-cell lung cancer with methylthioadenosine phosphorylase (MTAP) deficiency.
    Ashok Kumar P; Graziano SL; Danziger N; Pavlick D; Severson EA; Ramkissoon SH; Huang RSP; Decker B; Ross JS
    Cancer Med; 2023 Jan; 12(2):1157-1166. PubMed ID: 35747993
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatments, Outcomes, and Validity of Prognostic Scores in Patients With Sarcomatoid Renal Cell Carcinoma: A 20-Year Single-Institution Experience.
    Korenbaum C; Pierard L; Thiéry A; Story F; Lindner V; Lang H; Kurtz JE; Barthélémy P
    Clin Genitourin Cancer; 2018 Jun; 16(3):e577-e586. PubMed ID: 29395949
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular Subsets in Renal Cancer Determine Outcome to Checkpoint and Angiogenesis Blockade.
    Motzer RJ; Banchereau R; Hamidi H; Powles T; McDermott D; Atkins MB; Escudier B; Liu LF; Leng N; Abbas AR; Fan J; Koeppen H; Lin J; Carroll S; Hashimoto K; Mariathasan S; Green M; Tayama D; Hegde PS; Schiff C; Huseni MA; Rini B
    Cancer Cell; 2020 Dec; 38(6):803-817.e4. PubMed ID: 33157048
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PD-1 and PD-L1 Expression in Renal Cell Carcinoma with Sarcomatoid Differentiation.
    Joseph RW; Millis SZ; Carballido EM; Bryant D; Gatalica Z; Reddy S; Bryce AH; Vogelzang NJ; Stanton ML; Castle EP; Ho TH
    Cancer Immunol Res; 2015 Dec; 3(12):1303-7. PubMed ID: 26307625
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genomic landscape of metastatic breast cancer (MBC) patients with methylthioadenosine phosphorylase (
    Bou Zerdan M; Ashok Kumar P; Haroun E; Srivastava N; Ross J; Sivapiragasam A
    Oncotarget; 2023 Mar; 14():178-187. PubMed ID: 36913304
    [TBL] [Abstract][Full Text] [Related]  

  • 9.
    Klümper N; Ralser DJ; Zarbl R; Schlack K; Schrader AJ; Rehlinghaus M; Hoffmann MJ; Niegisch G; Uhlig A; Trojan L; Steinestel J; Steinestel K; Wirtz RM; Sikic D; Eckstein M; Kristiansen G; Toma M; Hölzel M; Ritter M; Strieth S; Ellinger J; Dietrich D
    J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34446578
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A genomic mutation spectrum of collecting duct carcinoma in the Chinese population.
    Zhang H; Lu X; Huang G; Hua M; Zhang W; Wang T; Huang L; Wang Z; Chen Q; Li J; Yang Q; Yang G
    BMC Med Genomics; 2022 Jan; 15(1):1. PubMed ID: 34980126
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genomic Profiling and Response to Immune Checkpoint Inhibition plus Tyrosine Kinase Inhibition in FH-Deficient Renal Cell Carcinoma.
    Xu Y; Kong W; Cao M; Wang J; Wang Z; Zheng L; Wu X; Cheng R; He W; Yang B; Dong B; Pan J; Chen Y; Huang J; Jiang C; Zhai W; Li F; Chen R; Zhou X; Wu G; Geng X; Chen J; An H; Yuan Y; Xu T; Chen D; Lin D; Xu L; Huang K; Peng L; Yu Y; Tai S; Qi H; Luo K; Kang X; Wang H; Huang Y; Zhang J; Xue W
    Eur Urol; 2023 Feb; 83(2):163-172. PubMed ID: 35715365
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disordered methionine metabolism in MTAP/CDKN2A-deleted cancers leads to dependence on PRMT5.
    Mavrakis KJ; McDonald ER; Schlabach MR; Billy E; Hoffman GR; deWeck A; Ruddy DA; Venkatesan K; Yu J; McAllister G; Stump M; deBeaumont R; Ho S; Yue Y; Liu Y; Yan-Neale Y; Yang G; Lin F; Yin H; Gao H; Kipp DR; Zhao S; McNamara JT; Sprague ER; Zheng B; Lin Y; Cho YS; Gu J; Crawford K; Ciccone D; Vitari AC; Lai A; Capka V; Hurov K; Porter JA; Tallarico J; Mickanin C; Lees E; Pagliarini R; Keen N; Schmelzle T; Hofmann F; Stegmeier F; Sellers WR
    Science; 2016 Mar; 351(6278):1208-13. PubMed ID: 26912361
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Challenges and limitation of MTAP immunohistochemistry in diagnosing desmoplastic mesothelioma/sarcomatoid pleural mesothelioma with desmoplastic features.
    Sa-Ngiamwibool P; Hamasaki M; Kinoshita Y; Matsumoto S; Sato A; Tsujimura T; Kasai T; Hiroshima K; Kushitani K; Takeshima Y; Kawahara K; Iwasaki A; Nabeshima K
    Ann Diagn Pathol; 2022 Oct; 60():152004. PubMed ID: 35797798
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sarcomatoid mesothelioma originating from mesothelioma in situ: are methylthioadenosine phosphorylase loss and CDKN2A homozygous deletion poor prognostic factors for preinvasive mesothelioma?
    Nishikubo M; Jimbo N; Tanaka Y; Tachihara M; Itoh T; Maniwa Y
    Virchows Arch; 2022 Aug; 481(2):307-312. PubMed ID: 35043235
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Clinical Activity of PD-1/PD-L1 Inhibitors in Metastatic Non-Clear Cell Renal Cell Carcinoma.
    McKay RR; Bossé D; Xie W; Wankowicz SAM; Flaifel A; Brandao R; Lalani AA; Martini DJ; Wei XX; Braun DA; Van Allen E; Castellano D; De Velasco G; Wells JC; Heng DY; Fay AP; Schutz FA; Hsu J; Pal SK; Lee JL; Hsieh JJ; Harshman LC; Signoretti S; Motzer RJ; Feldman D; Choueiri TK
    Cancer Immunol Res; 2018 Jul; 6(7):758-765. PubMed ID: 29748390
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patients with sarcomatoid renal cell carcinoma - re-defining the first-line of treatment: A meta-analysis of randomised clinical trials with immune checkpoint inhibitors.
    Iacovelli R; Ciccarese C; Bria E; Bracarda S; Porta C; Procopio G; Tortora G
    Eur J Cancer; 2020 Sep; 136():195-203. PubMed ID: 32712550
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fine-mapping loss of gene architecture at the CDKN2B (p15INK4b), CDKN2A (p14ARF, p16INK4a), and MTAP genes in head and neck squamous cell carcinoma.
    Worsham MJ; Chen KM; Tiwari N; Pals G; Schouten JP; Sethi S; Benninger MS
    Arch Otolaryngol Head Neck Surg; 2006 Apr; 132(4):409-15. PubMed ID: 16618910
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gut Bacteria Composition Drives Primary Resistance to Cancer Immunotherapy in Renal Cell Carcinoma Patients.
    Derosa L; Routy B; Fidelle M; Iebba V; Alla L; Pasolli E; Segata N; Desnoyer A; Pietrantonio F; Ferrere G; Fahrner JE; Le Chatellier E; Pons N; Galleron N; Roume H; Duong CPM; Mondragón L; Iribarren K; Bonvalet M; Terrisse S; Rauber C; Goubet AG; Daillère R; Lemaitre F; Reni A; Casu B; Alou MT; Alves Costa Silva C; Raoult D; Fizazi K; Escudier B; Kroemer G; Albiges L; Zitvogel L
    Eur Urol; 2020 Aug; 78(2):195-206. PubMed ID: 32376136
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The significance of sarcomatoid and rhabdoid dedifferentiation in renal cell carcinoma.
    Hahn AW; Lebenthal J; Genovese G; Sircar K; Tannir NM; Msaouel P
    Cancer Treat Res Commun; 2022; 33():100640. PubMed ID: 36174377
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular determinants of response to PD-L1 blockade across tumor types.
    Banchereau R; Leng N; Zill O; Sokol E; Liu G; Pavlick D; Maund S; Liu LF; Kadel E; Baldwin N; Jhunjhunwala S; Nickles D; Assaf ZJ; Bower D; Patil N; McCleland M; Shames D; Molinero L; Huseni M; Sanjabi S; Cummings C; Mellman I; Mariathasan S; Hegde P; Powles T
    Nat Commun; 2021 Jun; 12(1):3969. PubMed ID: 34172722
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.